Publications
5674 Results
- Journal / Conference
- American Urological Association Annual Meeting (April 26-29 (Saturday-Tuesday, Las Vegas NV)
- Year
- 2025
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217
Effect of finasteride on urinary outcomes after benign prostatic hyperplasia surgery: secondary analysis of the Prostate Cancer Prevention Trial
- Journal / Conference
- ENETS (European Neuroendocrine Tumor Society) meeting (Mar 5-7, 2025, Krakow, Poland)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/A021602
Efficacy and Safety of Cabozantinib for Advanced Grade 3 Neuroendocrine Tumors After Progression on Prior Therapy: Subgroup Analysis of the Phase 3 CABINET Trial (Alliance A021602)
- Journal / Conference
- AACR Annual Meeting (April 25-30, 2025, Chicago, IL)
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80702
Prognostic and predictive role of T cell infiltration in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
- Journal / Conference
- Society for Clinical Trials (May 18-21, 2025, Vancouver, CAN)
- Year
- 2025
- Research Committee(s)
- Multiple sites
Harnessing Artificial intelligence in Data Management
- Journal / Conference
- AACR 2025 Meeting, poster; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT092
- Year
- 2025
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Vaginal Cancers
- Journal / Conference
- Nature Medicine
- Year
- 2025
- Research Committee(s)
- Melanoma
- PMID
- PMID40813711
- Study Number(s)
- S1512
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial
- Journal / Conference
- ASCO Annual Meeting (May 30-June 3, 2025, Chicago, IL), oral, Abstract # LBA9507
- Year
- 2025
- Research Committee(s)
- Melanoma
- Study Number(s)
- S2000
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT# 04511013)
- Journal / Conference
- ASCO Annual Meeitng (May 30-June 3, 2025, Chicago), rapid oral, Abstract # 8518
- Year
- 2025
- Research Committee(s)
- Lung
- Study Number(s)
- S1900E
(S1900E: A Phase II Study of AMG 510 in Patients With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-Map Sub-Study))
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), publication only, Abstract # e17109
- Year
- 2025
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216)
- Journal / Conference
- ICML 2025 Meeting (Lugano, Switzerland, from 17 to 21 June 2025)
- Year
- 2025
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826